Letrozole Tablet, Film Coated
Product Images NDC 62135-491

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 62135-491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Letrozole Tablets, Usp (NDC 62135-491-30)

Letrozole Tablets, Usp (NDC 62135-491-30)
Letrozole 2.5 mg film-coated tablets packaging label showing the product name, strength, dosage form, and quantity of 30 tablets. Label indicates the drug is Rx only and contains FD&C Yellow No. 5 as a color additive. The labeler is Chartwell Rx, LLC. Storage instructions and manufacturing details are also visible.*
FDA Label Image

Letrozole Tablets, Usp (NDC 62135-491-90)

Letrozole Tablets, Usp (NDC 62135-491-90)
Letrozole Tablets, USP 2.5 mg film-coated oral tablets in a 90-tablet package. The label states prescription use only and notes the presence of FD&C Yellow No.5 (tartrazine) as a color additive. Manufactured by Chartwell RX, LLC.*
FDA Label Image

Figure 1 (Letrozole Figure 1)

Figure 1 (Letrozole Figure 1)
A Kaplan-Meier survival curve comparing Letrozole and Tamoxifen treatments over 72 months. The y-axis represents the proportion surviving from 0.0 to 1.0, and the x-axis shows time in months from 0 to 72. The solid line represents Letrozole, and the dashed line represents Tamoxifen, with patient counts at risk listed below the graph at various time points.*
FDA Label Image

Figure 2 (Letrozole Figure 2)

Figure 2 (Letrozole Figure 2)
A line graph comparing progression-free survival over time (in months) between two treatments: Letrozole 2.5 mg and Tamoxifen 20 mg. The y-axis represents the proportion of patients progression-free, ranging from 0 to 1, and the x-axis represents time in months, ranging from 0 to 60.*
FDA Label Image

Figure 3 (Letrozole Figure 3)

Figure 3 (Letrozole Figure 3)
A survival curve chart compares the proportion of patients alive over a time period of 0 to 54 months. Two lines represent treatment groups: Letrozole first (solid line) and Tamoxifen first (dashed line). Both lines show a decline in survival over time, converging near 30 months, with survival proportions decreasing below 0.4 by 54 months.*
FDA Label Image

Figure 4 (Letrozole Figure 4)

Figure 4 (Letrozole Figure 4)
A Kaplan-Meier survival curve chart depicting 'Time to Progression (in Days)' on the x-axis and probability on the y-axis. It compares treatment groups including Letrozole 0.5 mg, Letrozole 2.5 mg, and MA, with separate lines representing each group over time up to approximately 900 days.*
FDA Label Image

Figure 5 (Letrozole Figure 5)

Figure 5 (Letrozole Figure 5)
A Kaplan-Meier survival curve graph showing time to progression (in days) for different treatment groups of Letrozole 0.5 mg and Letrozole 2.5 mg. The Y-axis represents progression proportion from 1.0 to 0, and the X-axis shows time in days from 0 to 900. The graph compares progression rates over time for the two dosage groups.*
FDA Label Image

Letrozole-structure (Letrozole Structure)

Letrozole-structure (Letrozole Structure)
Chemical structure of Letrozole, showing the molecular arrangement with two cyanophenyl groups connected to a triazole ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.